In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)- 2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABA_A receptor α5 subtype-selective inverse agonist

John R. Atack, Karen A. Maubach, Keith A. Wafford, Desmond O'Connor, A. David Rodrigues, David C. Evans, F. David Tattersall, Mark S. Chambers, Angus M. MacLeod, Wai Si Eng, Christine Ryan, Eric Hostetler, Sandra M. Sanabria, Raymond E. Gibson, Stephen Krause, H. Donald Burns, Richard J. Hargreaves, Nancy G B Agrawal, Ruth M. McKernan, M. Gail MurphyKevin Gingrich, Gerard R. Dawson, Donald G. Musson, Kevin J. Petty

Anesthesiology & Pain Management - Chairman's Office - Administration
Anesthesiology & Pain Management

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Sort by
Weight
Alphabetically

In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)- 2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABA_A receptor α5 subtype-selective inverse agonist

Fingerprint

Medicine & Life Sciences

In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)- 2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor α5 subtype-selective inverse agonist

Fingerprint

Medicine & Life Sciences

In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)- 2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABA_A receptor α5 subtype-selective inverse agonist